My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 133

    1.

    Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.

    Bernard L, Vuagnat A, Peytavin G, Hallouin MC, Bouhour D, Nguyen TH, Vildé JL, Bricaire F, Raguin G, de Truchis P, Ghez D, Duong M, Perronne C.

    Ann Intern Med. 2002 Oct 15;137(8):656-9.PMID: 12379065 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment.

    [No authors listed]

    Ann Intern Med. 2002 Oct 15;137(8):I48. No abstract available. PMID: 12379092 [PubMed - indexed for MEDLINE]Related articles

    3.

    Hair it is: the long and short of monitoring antiretroviral treatment.

    Gandhi M, Greenblatt RM.

    Ann Intern Med. 2002 Oct 15;137(8):696-7. No abstract available. PMID: 12379072 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.

    Servais J, Peytavin G, Arendt V, Staub T, Schneider F, Hemmer R, Burtonboy G, Schmit JC.

    AIDS. 2001 May 4;15(7):941-3. No abstract available. PMID: 11399971 [PubMed - indexed for MEDLINE]Related articles

    5.

    Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

    van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

    Pediatr Infect Dis J. 2002 Aug;21(8):743-7.PMID: 12192162 [PubMed - indexed for MEDLINE]Related articles

    6.

    Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures.

    Campo RE, Moreno JN, Suarez G, Miller N, Kolber MA, Holder DJ, Shivaprakash M, DeAngelis DM, Wright JL, Schleif WA, Emini EA, Condra JH.

    AIDS. 2003 Sep 5;17(13):1933-9.PMID: 12960826 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

    Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group.

    J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. Erratum in: J Acquir Immune Defic Syndr. 2003 Jan;32(1):116.. PMID: 12473833 [PubMed - indexed for MEDLINE]Related articles

    8.

    Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.

    Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C; APROCO Study Group.

    Ther Drug Monit. 2005 Feb;27(1):63-70. Erratum in: Ther Drug Monit. 2005 Aug;27(4):table of contents. PMID: 15665749 [PubMed - indexed for MEDLINE]Related articles

    9.

    Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART.

    Tozzi V, Bellagamba R, Castiglione F, Amendola A, Ivanovic J, Nicastri E, Libertone R, D'Offizi G, Liuzzi G, Gori C, Forbici F, D'Arrigo R, Bertoli A, Salvatori MF, Capobianchi MR, Antinori A, Perno CF, Narciso P.

    AIDS Res Hum Retroviruses. 2008 Jun;24(6):787-96.PMID: 18507523 [PubMed - indexed for MEDLINE]Related articles

    10.

    Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.

    Polis MA, Suzman DL, Yoder CP, Shen JM, Mican JM, Dewar RL, Metcalf JA, Falloon J, Davey RT Jr, Kovacs JA, Feinberg MB, Masur H, Piscitelli SC.

    AIDS. 2003 May 23;17(8):1167-72.PMID: 12819518 [PubMed - indexed for MEDLINE]Related articles

    11.

    Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.

    Cahn P, Vibhagool A, Schechter M, Soto-Ramirez L, Carosi G, Smaill F, Jordan JC, Pharo CE, Thomas NE, Steel HM.

    Curr Med Res Opin. 2004 Jul;20(7):1115-23.PMID: 15265256 [PubMed - indexed for MEDLINE]Related articles

    12.

    Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.

    Urban AW, Bean P, Aziz D, Graziano FM, Neudeck BL.

    Int J STD AIDS. 2003 Feb;14(2):103-8.PMID: 12662388 [PubMed - indexed for MEDLINE]Related articles

    13.

    Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.

    de la Rosa R, Ruíz-Mateos E, Rubio A, Abad MA, Vallejo A, Rivero L, Genebat M, Sánchez-Quijano A, Lissen E, Leal M.

    J Antimicrob Chemother. 2004 Jan;53(1):95-101. Epub 2003 Dec 4.PMID: 14657091 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Lopinavir/ritonavir: a review of its use in the management of HIV infection.

    Cvetkovic RS, Goa KL.

    Drugs. 2003;63(8):769-802. Review.PMID: 12662125 [PubMed - indexed for MEDLINE]Related articles

    15.

    Differences in durability of treatment with initial PI-based regimens.

    Pérez-Elías MJ, Moreno A, Moreno S, Antela A, Dronda F, Muñoz V, Casado JL, Quereda C, Lopez D, Navas E.

    HIV Clin Trials. 2003 Nov-Dec;4(6):391-9.PMID: 14628282 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

    Røge BT, Katzenstein TL, Nielsen HL, Gerstoft J.

    HIV Med. 2003 Jan;4(1):38-47.PMID: 12534958 [PubMed - indexed for MEDLINE]Related articles

    17.

    Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

    Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

    AIDS. 2003 Jul;17 Suppl 3:S31-8.PMID: 14565607 [PubMed - indexed for MEDLINE]Related articles

    18.

    Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

    Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM; BEST Study Team.

    AIDS. 2003 Apr 11;17(6):831-40.PMID: 12660530 [PubMed - indexed for MEDLINE]Related articles

    19.

    Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.

    Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, Lackritz E.

    AIDS. 2003 Jul;17 Suppl 3:S39-48.PMID: 14565608 [PubMed - indexed for MEDLINE]Related articles

    20.

    Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

    Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

    Ann Intern Med. 2007 Apr 17;146(8):564-73.PMID: 17438315 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity